To screen ETFs by asset class, performance, yield and more, check out the
View as an RSS Feed
Shares of Amarin (
) spike lower after the FDA's latest
Orange Book update
shows no change in the status of its fish-oil pill Vascepa. M&A speculators had been optimistic on a
decision from regulators
over the exclusivity of the pill would be coming this month, because last week a draft response letter made the rounds around the FDA which made no mention of 'no decision' this month, as it has previously before.
View news story
Novice invester. Could someone please tell me why 90% of todays volume took place after 1:15 PM ET. Optimist that I am I'd like to think that SEC rules require that a possible acquirer of amrn had to divest themselves of shares to get below a certain trigger point between tender offer and hostile takeover. wouldn't that be nice.
Nov 17, 2012. 06:12 AM
Link to Comment
Xignite quote data
© 2014 Seeking Alpha